Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales growth.
The post What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle appeared first on Investor's Business Daily.